WELCOME TO FIERCE LIFE SCIENCES WEEKLY DIGEST The year so far has seen an unprecedented number of layoffs in the biotech industry. And while phrases like “workforce reduction” and “reducing headcount” aim to avoid facing the human element, real people’s lives are being disrupted by these difficult corporate decisions, not to mention the science they pursue. Fierce Biotech looked at the 10 most game-changing layoffs in 2022 to date. Meanwhile, generic drugmakers took a hit last year with stagnant sales and increased pressures from competition. Fierce Pharma breaks down the top 10 generic drugmakers by 2021 revenue. Those stories, plus our top reads of the week, follow below. | |
|
Featured Story | By Fraiser Kansteiner While reimbursement and education challenges persist, drugmakers like Eli Lilly and Novo Nordisk are poised to unlock a global obesity market that could be worth more than $50 billion by the end of the decade, analysts at Morgan Stanley Research wrote in a note to clients Friday. read more |
| |
|---|
|
Top Stories Of The Week By Annalee Armstrong In a sign of just how tough neuroscience is, Biogen is cutting a clutch of programs from its Alzheimer’s disease, amyotrophic lateral sclerosis and schizophrenia pipelines. read more By Kevin Dunleavy,Zoey Becker,Fraiser Kansteiner,Angus Liu,Eric Sagonowsky Many producers of generic drugs have struggled to achieve growth in recent years due to pricing pressures. But there are promising signs that the industry is ready for an uptick, and they were evident in 2021 as eight of the top 10 companies by generics sales realized growth. read more By Annalee Armstrong At the halfway point for the year, Fierce Biotech looks back at some of the most important layoff events that have hit the industry in 2021. read more By Max Bayer Japanese Big Pharma Eisai is shutting down its U.S.-based oncology R&D wing, H3 Biomedicine, saying the operation was "complete." As a result, the company is laying off 88 staffers. read more By Andrea Park Genetic testing company Invitae will lay off more than 1,000 employees as part of a year-long restructuring plan that’s expected to ultimately save the company hundreds of millions of dollars annually. read more By Angus Liu Just as Biogen’s multiple sclerosis franchise is under serious threat from generics and new competition, the company has decided to pay top dollar to settle a long-running kickback lawsuit centered on the drugs. read more By Zoey Becker Come Monday, GSK and consumer health unit Haleon will officially part ways, leaving the Big Pharma's biopharma and vaccines divisions to stand on their own. Will CEO Emma Walmsley reach for new M&A? read more By Andrea Park In the wake of the FDA handing down its first clearance for an in vitro test for early-stage Alzheimer’s disease in May, the floodgates have been opened. read more By Ben Adams Grey’s Anatomy actor Patrick Dempsey sits down with Amgen and charity StoryCorps to share his personal cancer story. read more By Kevin Dunleavy Samsung has acquired additional land in Incheon, South Korea, on which to construct a new duplicate facility, Bio Campus II. The parcel was purchased for 426 billion won ($323 million) and is 30% larger than Samsung’s original campus. By 2032, it will house 4,000 employees—or roughly 400 new hires per year, Samsung said during a signing ceremony Monday at Incheon City Hall. read more By Max Bayer New research from Germany hints at the promise of treating cancer with bacteria-based 'microrobots' armed with nanoliposomes containing immune system-triggering drugs. The scientists found that the bacteria, guided by magnets, was more effective at killing cancer cells than a control group. read more By Teresa Carey This week on "The Top Line," we discuss the significant increase in layoffs and what that means for the biotech industry. Also under discussion is our special report on the top 10 companies by generic drugs sales. read more |  | On Demand Webinar: Automating Cell Therapy Product Now Available on Demand The major key cost drivers of the autologous CAR T-cell therapy are generally QC analytics and biocharacterization of viral vector and supporting starting biomaterials, all of which could be developed and managed in-house. The cost and impacts revealed through the decision-making process emphasize the need for automation. Watch now to learn more. |
|---|
Resources Sponsored by: NetApp Could cloud be the cure for your EHR headaches? See our infographic on how moving to the cloud can slash financial and administrative burdens. Sponsored by: Triangle Insights Group, LLC Discover how the new partnership between TrialCard and Triangle Insights Group can help you bridge the critical gap between strategy and execution, ensuring commercialization success of your product or therapy. Sponsored by: Nexelis Discover Nexelis’ first-hand perspective on how to develop innovative, agile solutions in vaccine efficacy testing in this exclusive e-book. Sponsored by: Cognizant Explore how Cognizant SIP helped Roche streamline its global feasibility process. Sponsored by: Blue Matter Consulting This e-book covers the 12 most common pitfalls for companies entering European markets for the first time, offering guidance to help growing companies avoid them and succeed. Sponsored by: Catalent What is the most suitable dosage form technology for the Oral Delivery of Lipid-Based Formulations? Sponsored by: Catalent Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care. Sponsored by: Catalent Did you know Catalent has newly expanded in-house capabilities spanning clinical and commercial scale manufacturing for DPIs, unit-dose, bi-dose and preserved multi-dose nasal sprays? Sponsored by: Thermo Fisher Scientific The journey for starting or expanding a lab can be exhilarating, while also being challenging--learn how this free program provides savings and solutions to support your goals. Sponsored by: Catalent What are key considerations for intranasal delivery in the treatment of acute and chronic conditions? Sponsored by: Catalent Orally Inhaled & Nasal Drug Delivery: A Pipeline of Opportunities Sponsored by: Catalent Learn more about how the versatility of Softgel Technology helped a customer with a volatile compound. Sponsored by: Catalent How can Lipid-Based Drug Delivery System help bring poorly soluble drugs to market? Sponsored by: Catalent Carla Vozone discusses the significant trends in the OINDP segment including large molecules and novel indications, changes within CDMOs and various challenges facing the industry. Sponsored by: Catalent Did you know Catalent has newly expanded in-house capabilities spanning clinical and commercial scale manufacturing for DPIs, unit-dose, bi-dose and preserved multi-dose nasal sprays? Sponsored by: Catalent Ypsomed and Catalent Biologics experts discuss strategies for integrated PFS manufacturing and auto-injector assembly to accelerate timelines and more in this webinar. | 
